Starpharma 1H losses grow on trial spending


By Dylan Bushell-Embling
Tuesday, 17 February, 2015

Starpharma (ASX:SPL) widened its loss for the half-year ending in December, but still ended the period in a strong cash position of $39.3 million.

The company’s reported loss grew to $8.5 million, up from $5.6 million in the same period a year earlier.

Spending on the company’s clinical programs, including two phase III trials of antimicrobial gel VivaGel for the prevention of bacterial vaginosis, contributed to the wider loss.

The company is also involved in a phase I study of DEP-docetaxel, the dendrimer-enhanced formulation of the popular chemotherapeutic.

Starpharma’s cash balance of $39.3 million improved from $24 million at the start of the half-year period, thanks to the injection of $20.5 million in net proceeds from a placement and share purchase plan.

Another key milestone involved the first sales of the dual-branded Starpharma-Ansell VivaGel coated condom in Australia through Woolworths retail stores.

The companies also received regulatory approval in New Zealand, but fellow licensee Okamoto faced regulatory delays for its own VivaGel coated condom in Japan.

Starpharma meanwhile received a $4.2 million R&D tax incentive rebate during the period.

Starpharma (ASX:SPL) shares were trading 7.29% higher at $0.515 as of around 1 pm on Monday

Related News

Does exercise really extend lifespan? It's complicated

Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd